Univariate and multivariate analyses
| . | Relative benefit for survival . | Confidence interval . | P . |
|---|---|---|---|
| Univariate analysis | |||
| CR/CRu after CVP, CR vs non-CR | 3.32 | 1.1-10.2 | .033 |
| Anti-Id antibody response, negative vs positive | 0.355 | 0.132-0.957 | .041 |
| Anti-Id cellular response, negative vs positive | 1.09 | 0.42-2.85 | .86 |
| Age at diagnosis ≤ 60 y vs > 60 y | 1.02 | 0.977-1.07 | .37 |
| FLIPI, low vs high | 1.65 | 0.274-9.96 | .58 |
| FLIPI, intermediate vs high | 1.97 | 0.435-8.90 | .38 |
| Multivariate analysis | |||
| CR/CRu after CVP, CR vs non-CR | 3.28 | 0.305-1.071 | .037 |
| Anti-Id antibody response, negative vs positive | 0.360 | 0.132-0.988 | .047 |
| . | Relative benefit for survival . | Confidence interval . | P . |
|---|---|---|---|
| Univariate analysis | |||
| CR/CRu after CVP, CR vs non-CR | 3.32 | 1.1-10.2 | .033 |
| Anti-Id antibody response, negative vs positive | 0.355 | 0.132-0.957 | .041 |
| Anti-Id cellular response, negative vs positive | 1.09 | 0.42-2.85 | .86 |
| Age at diagnosis ≤ 60 y vs > 60 y | 1.02 | 0.977-1.07 | .37 |
| FLIPI, low vs high | 1.65 | 0.274-9.96 | .58 |
| FLIPI, intermediate vs high | 1.97 | 0.435-8.90 | .38 |
| Multivariate analysis | |||
| CR/CRu after CVP, CR vs non-CR | 3.28 | 0.305-1.071 | .037 |
| Anti-Id antibody response, negative vs positive | 0.360 | 0.132-0.988 | .047 |